Merck & Co., Inc. (MRK)'s Januvia Linked To Increase In Heart Failure Hospitalizations
7/7/2014 5:56:09 AM
The cardiovascular effects of drugs used for glucose control in patients with diabetes have been a subject of controversy for many years now. More recently, attention has started to focus specifically on the risk for heart failure. Now, an observational study will likely raise new questions about the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin (Januvia, Merck).
Help employers find you! Check out all the jobs and post your resume.
comments powered by